Mendelian randomization studies of LDL-C have found an odds ratio for coronary disease of ≈2 per 1 mmol/L higher LDL-C, which is much stronger than the effect seen in statin trials24 and so suggest that only a third to a half of the coronary risk per unit LDL-C from lifelong genetically elevated LDL-C is reversed within a few years of statin therapy.24,25 Assuming the same holds for Lp(a) then, taken together, the literature suggests that therapeutic lowering of Lp(a) during a trial might be expected to produce a 15% to 20% reduction in coronary risk per 100 nmol/L lower Lp(a). This evidence concerns the gene LPA and coronary artery disorder.